Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXO in metastatic gastric or gastroesophageal adenocarcinoma
NCT01129310Phase 2Completed
- Sponsor
- American Health Staffing Group
- Start
- Jul 2010
- Primary completion
- May 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by American Health Staffing Group. Primary endpoints: Overall Response Rate at 2 years and Dose Limiting Toxicity at 2 years. Started Jul 2010; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01129310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01129310.